Pregled bibliografske jedinice broj: 661491
Mutations in HNF1A result in marked alterations of plasma glycan profile.
Mutations in HNF1A result in marked alterations of plasma glycan profile. // Diabetes (New York, N.Y.), 62 (2012), 4; 1329-1337 doi:10.2337/db12-0880 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 661491 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Mutations in HNF1A result in marked alterations of plasma glycan profile.
Autori
Thanabalasingham, G. ; Huffman, J.E. ; Kattla, J.J. ; Novokmet, Mislav ; Rudan, Igor ; Gloyn, A.L. ; Hayward, C. ; Adamczyk, B. ; Reynolds, R.M. ; Mužinić, Ana ; Hassanali, N. ; Pučić, Maja ; Bennett, A.J. ; Essafi, A. ; Polašek, Ozren ; Mughal, S.A. ; Redžić, Irma ; Primorac, Dragan ; Zgaga, Lina ; Kolčić, Ivana ; Hansen, T. ; Gasperikova, D. ; Tjora, E. ; Strachan, M.W. ; Nielsen, T. ; Stanik, Juraj ; Klimes, I. ; Pedersen, O.B. ; Njølstad, P.R. ; Wild, S.H. ; Gyllensten, U. ; Gornik, Olga ; Wilson, J.F. ; Hastie, N.D. ; Campbell, H. ; McCarthy, M.I. ; Rudd, P.M. ; Owen, K.R. ; Lauc, Gordan ; Wright, A.F.
Izvornik
Diabetes (New York, N.Y.) (0012-1797) 62
(2012), 4;
1329-1337
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
diabetes; MODY; glycosylation
Sažetak
A recent genome-wide association study identified hepatocyte nuclear factor 1-α (HNF1A) as a key regulator of fucosylation. We hypothesized that loss-of-function HNF1A mutations causal for maturity-onset diabetes of the young (MODY) would display altered fucosylation of N-linked glycans on plasma proteins and that glycan biomarkers could improve the efficiency of a diagnosis of HNF1A- MODY. In a pilot comparison of 33 subjects with HNF1A-MODY and 41 subjects with type 2 diabetes, 15 of 29 glycan measurements differed between the two groups. The DG9-glycan index, which is the ratio of fucosylated to nonfucosylated triantennary glycans, provided optimum discrimination in the pilot study and was examined further among additional subjects with HNF1A-MODY (n = 188), glucokinase (GCK)-MODY (n = 118), hepatocyte nuclear factor 4-α (HNF4A)-MODY (n = 40), type 1 diabetes (n = 98), type 2 diabetes (n = 167), and nondiabetic controls (n = 98). The DG9- glycan index was markedly lower in HNF1A-MODY than in controls or other diabetes subtypes, offered good discrimination between HNF1A-MODY and both type 1 and type 2 diabetes (C statistic ≥ 0.90), and enabled us to detect three previously undetected HNF1A mutations in patients with diabetes. In conclusion, glycan profiles are altered substantially in HNF1A-MODY, and the DG9-glycan index has potential clinical value as a diagnostic biomarker of HNF1A dysfunction.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
309-0061194-2023 - Glikoproteomika stresa i bolesti povezanih sa stresom
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Split,
Medicinski fakultet, Osijek,
GENOS d.o.o.
Profili:
Olga Gornik Kljaić
(autor)
Ozren Polašek
(autor)
Gordan Lauc
(autor)
Mislav Novokmet
(autor)
Ana Mužinić
(autor)
Igor Rudan
(autor)
Ivana Kolčić
(autor)
Maja Pučić Baković
(autor)
Lina Zgaga
(autor)
Dragan Primorac
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE